期刊
NEPHRON
卷 92, 期 1, 页码 200-202出版社
KARGER
DOI: 10.1159/000064461
关键词
mesalazine; inflammatory bowel disease; interstitial nephritis; end-stage renal failure; monitoring renal function
Background. In the last 10 years several reports have linked oral 5-aminosalicylic acid (5-ASA) therapy to acute and chronic tubulointerstitial nephritis, but to our knowledge only 2 patients have been reported with terminal end-stage renal disease due to mesalazine (5-ASA). After 1 year of treatment with 5-ASA annual monitoring of serum creatinine is recommended. Results: We report the development of end-stage renal disease in a patient 10 months after the last assessment of serum creatinine, which was normal at 71 mumol/l. Conclusion: Because of this dangerous side effect, we would like to recommend 6-monthly assessment of renal function. Copyright (C) 2002 S. Karger AG, Basel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据